Please wait a minute...
Reviews in Cardiovascular Medicine  2015, Vol. 16 Issue (4): 225-234     DOI: 10.3909/ricm0779
Review | Next articles
Cardiotoxicity of Anticancer Therapies
Raghunandan Muppidi1, Laura Spranklin2, William Scialla2, Nauman Islam1, Ronald Freudenberger1, Robert Malacoff1
1 Department of Cardiology, Lehigh Valley Health Network, Allentown, PA
2 Department of Hematology-Oncology, Lehigh Valley Health Network, Allentown, PA
Download:  PDF(232KB)  ( 80 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
Cardiovascular diseases and cancer continue to remain major causes of mortality and morbidity. However, overall cancer death rates have declined 20% from their peak in 1991. These declines reflect changing patterns in smoking, prevention, earlier diagnosis, and better treatment options in chemotherapy. It is recognized that this improved survival with better cancer therapies has put patients at risk for cardiovascular disease later in life; this may be secondary to risk factors for developing cardiovascular disease or the effect of anticancer therapies. Earlier detection, identifying patients at risk of developing cardiotoxicity, and early institution of treatment are paramount to decreasing morbidity associated with cardiotoxicity. Adverse cardiac effects have been observed and reported with a wide variety of chemotherapeutic agents. Herein we review cardiac effects of some of the common agents used in oncology.
Key words:  Cardiotoxicity      Anticancer therapy      Coronary artery disease      Cardiomyopathy     
Published:  30 December 2015     

Cite this article: 

Raghunandan Muppidi, Laura Spranklin, William Scialla, Nauman Islam, Ronald Freudenberger, Robert Malacoff. Cardiotoxicity of Anticancer Therapies. Reviews in Cardiovascular Medicine, 2015, 16(4): 225-234.

URL: 

https://rcm.imrpress.com/EN/10.3909/ricm0779     OR     https://rcm.imrpress.com/EN/Y2015/V16/I4/225

[1] Meer Fakhry, Mandeep S. Sidhu, Sripal Bangalore, Roy O. Mathew. Accelerated and intensified calcific atherosclerosis and microvascular dysfunction in patients with chronic kidney disease[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 157-162.
[2] Nidhi Madan, Dinesh Kalra. Clinical evaluation of infiltrative cardiomyopathies resulting in heart failure with preserved ejection fraction[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 181-190.
[3] Anthony (Ming-yu) Chuang, Mau T Nguyen, Woon-Man Kung, Sam Lehman, Derek P Chew. High-sensitivity troponin in chronic kidney disease: Considerations in myocardial infarction and beyond[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 191-203.
[4] Zhanru Qi, Hongyan Zheng, Zhonghai Wei, Qing Dai, Jun Xie, Lian Wang, Jingmei Zhang, Jie Song. Short-term and long-term outcomes of bailout versus planned coronary rotational atherectomy[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 309-314.
[5] Yuhong Liu, Zhihuan Zeng, Xing Yu, Tudi Li, Yusi Yao, Rong Chen, Jianyi Zheng. Impact of lipoprotein(a) on long-term outcomes after percutaneous coronary intervention in patients with reduced low-density lipoprotein cholesterol[J]. Reviews in Cardiovascular Medicine, 2020, 21(1): 147-153.
[6] Akanksha Agrawal, Deepanshu Jain, Pradhum Ram, Jorge Luis Penalver Leon, Janani Rangaswami. Anticoagulation for intra-cardiac thrombi in peripartum cardiomyopathy: A review of the literature[J]. Reviews in Cardiovascular Medicine, 2019, 20(2): 53-58.
[7] Victoria E. Tril, Alla V. Burlutskaya, Lily V. Polischuk. Metabolic cardiomyopathy in pediatrics[J]. Reviews in Cardiovascular Medicine, 2019, 20(2): 73-80.
[8] Juan M. Vinardell, Christos G. Mihos, Adam Nader, Richard Ro, Esteban Escolar, Orlando Santana. Stress Cardiomyopathy in a Patient with Hypertrophic Cardiomyopathy: Case Presentation and Review of the Literature[J]. Reviews in Cardiovascular Medicine, 2018, 19(2): 65-68.
[9] Christian O. Koelbl, Zoran S. Nedeljkovic, Alice K. Jacobs. Coronary Chronic Total Occlusion (CTO): A Review[J]. Reviews in Cardiovascular Medicine, 2018, 19(1): 33-39.
[10] Saberio Lo Presti, Christos G. Mihos, Evin Yucel, Sofia A. Horvath, Orlando Santana. A Focused Review on the Pathophysiology, Diagnosis, and Management of Cardiac Amyloidosis[J]. Reviews in Cardiovascular Medicine, 2017, 18(4): 123-133.
[11] Akanksha Agrawal, Deepanshu Jain, Eyob L. Feyssa, Aman M. Amanullah. Utility of Dobutamine Stress Echocardiography in Cardiac Risk Stratification of Patients Undergoing Orthotopic Liver Transplantation[J]. Reviews in Cardiovascular Medicine, 2017, 18(4): 146-154.
[12] Swapnil Parve, Gulnaz I. Aliakberova, Albert A. Gylmanov, Diana I. Abdulganieva. Role of Exogenous Phosphocreatine in Chemotherapy-induced Cardiomyopathy[J]. Reviews in Cardiovascular Medicine, 2017, 18(2): 82-87.
[13] Mehul A. Pragani, Karan P. Desai, Doralisa Morrone, Mandeep S. Sidhu, William E. Boden. The Role of Nitrates in the Management of Stable Ischemic Heart Disease: A Review of the Current Evidence and Guidelines[J]. Reviews in Cardiovascular Medicine, 2017, 18(1): 14-20.
[14] George O. Adesina, Shelly A. Hall, Jose C. Mendez, Susan M. Joseph, Robert L. Gottlieb, Parag P. Kale, Amarinder S. Bindra. Arrhythmogenic Right Ventricular Dysplasia: An Under-recognized Form of Inherited Cardiomyopathy[J]. Reviews in Cardiovascular Medicine, 2017, 18(1): 37-43.
[15] Peter A. McCullough, Mohammad Kazem Fallahzadeh, Refaat M. Hegazi. Nutritional Deficiencies and Sarcopenia in Heart Failure: A Therapeutic Opportunity to Reduce Hospitalization and Death[J]. Reviews in Cardiovascular Medicine, 2016, 17(S1): 30-39.
No Suggested Reading articles found!